Mereo BioPharma Investors Urged to Act Before Class Action Deadline of April 6, 2026

Mereo BioPharma Securities Class Action Alert

The renowned law firm, Faruqi & Faruqi, LLP, has recently issued an alert reminding investors of Mereo BioPharma (NASDAQ: MREO) about a looming deadline for a federal securities class action. This alert is particularly significant for individuals who purchased or acquired shares of Mereo BioPharma between June 5, 2023, and December 26, 2025. The deadline to seek the role of lead plaintiff in the class action is set for April 6, 2026.

The law firm is actively investigating the potential claims against Mereo BioPharma, which has faced allegations that it violated federal securities laws. Specifically, the complaint accuses the company and its executives of providing false or misleading statements about the actual status of its Phase 3 clinical trials known as ORBIT and COSMIC. Allegedly, neither trial met its primary endpoint of reducing the annualized clinical fracture rate when compared to placebo or bisphosphonate control groups.

Faruqi & Faruqi has established itself as a notable national securities law firm with a robust track record, having recovered hundreds of millions of dollars for investors since its inception in 1995. With offices across New York, Pennsylvania, California, and Georgia, the firm has positioned itself as a credible advocate for those potentially harmed by corporate misconduct.

The process for becoming a lead plaintiff involves being the investor with the largest financial interest whose legal claims are typical of the larger class. Individuals interested in pursuing this option should initiate contact with counsel of their choice, while also having the option to remain an absent class member. Importantly, one's ability to benefit from any recovery made does not rely on the decision to become a lead plaintiff.

Investors holding any information regarding Mereo BioPharma's practices, including whistleblowers and former employees, are encouraged to reach out to Faruqi & Faruqi for further discussion.

Faruqi & Faruqi draws attention to the importance of this class action lawsuit and the rights of various stakeholders affected by Mereo BioPharma’s actions. As this situation continues to evolve, staying informed through legal updates and potential changes in stock performance is vital for current and prospective investors alike.

For more detailed information about this class action and to discuss your eligibility with an attorney, please visit Faruqi & Faruqi’s official website at www.faruqilaw.com/MREO or directly contact partner Josh Wilson at (877) 247-4292 or (212) 983-9330 (Ext. 1310).

This class action serves as a reminder of the essential rights investors possess and the responsibility of companies to maintain transparency and honesty in their communications. As the April 6 deadline approaches, affected investors are urged to act swiftly to ensure their voices are heard in this critical legal venue.